Article
Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma.
Molecular cancer therapeutics - 1 Dec 2014
Ilieva Kristina M, Correa Isabel, Josephs Debra H, Karagiannis Panagiotis, Egbuniwe Isioma U, Cafferkey Michiala J, Spicer James F, Harries Mark, Nestle Frank O, Lacy Katie E, Karagiannis Sophia N
Abstract excerpt
Malignant melanoma is associated with poor clinical prognosis; however, novel molecular and immune therapies are now improving patient outcomes. Almost 50% of melanomas harbor targetable activating mutations of BRAF that promote RAS-RAF-MEK-ERK pathway activation and melanoma proliferation. Recent evidence also indicates that melanomas bearing mutant BRAF may also have altered immune responses, suggesting...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.